Efficacy and safety of dual-targeted therapy in children with inflammatory bowel disease: Retrospective cohort study

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Pediatrics

ISSN

2219-2808

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.

World J Clin Pediatr. Mar 9, 2026; 15(1): 111093
Published online Mar 9, 2026. doi: 10.5409/wjcp.v15.i1.111093

Table 4 Dynamics of laboratory parameters depending on the lesion of the upper gastrointestinal tract in patients with Crohn’s disease

Parameter	Upper gastrointestinal tract lesions		P value
Parameter	No	Yes	P value
Нb at M3, median (IQR)	127.0 (122.0-134.0)	120.5 (117.8-121.0)	0.020^a
ESR at M3, median (SD)	10.8 (6.8)	28.5 (12.6)	0.004^a
CRP at M3, median (IQR)	1.0 (0.8-1.4)	0.8 (0.3-9.9)	0.905
Hb at M6, median (IQR)	129.0 (121.0-134.0)	121.0 (116.0-124.0)	0.109
ESR at M6, median (IQR)	6.0 (6.0-11.0)	19.0 (16.0-42.0)	0.019^a
CRP at M6, median (IQR)	0.6 (0.20-1.0)	1.0 (0.5-11.7)	0.283
Fecal calprotectin at M6, median (IQR)	175.0 (95.0-600.0)	600.0 (155.0-800.0)	0.421
simple endoscopic index of CD at M6, median (IQR)	0.0 (0.0-2.0)	10.0 (6.0-10.0)	0.042^a
Pediatric Crohn’s Disease Activity Index at M6, mean (SD)	3.6 (3.3)	11.5 (7.4)	0.016^a

^aP < 0.05.

CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; Hb: Hemoglobin; IQR: Interquartile range; M3: Three months; M6: Six months.

Citation: Gabrusskaya T, Ulanova N, Shilova E, Volkova N, Kilina S, Kornienko E, Kostik M. Efficacy and safety of dual-targeted therapy in children with inflammatory bowel disease: Retrospective cohort study. World J Clin Pediatr 2026; 15(1): 111093
URL: https://www.wjgnet.com/2219-2808/full/v15/i1/111093.htm
DOI: https://dx.doi.org/10.5409/wjcp.v15.i1.111093

Gabrusskaya T, Ulanova N, Shilova E, Volkova N, Kilina S, Kornienko E, Kostik M. Efficacy and safety of dual-targeted therapy in children with inflammatory bowel disease: Retrospective cohort study. World J Clin Pediatr 2026; 15(1): 111093 [PMID: 41884046 DOI: 10.5409/wjcp.v15.i1.111093]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.